Clear Search

Showing 1 result for “Connery L” published 2023.

October 2023

Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity

N Engl J Med. 2023; DOI: 10.1056/NEJMoa2302392

Orforglipron is a once-daily oral nonpeptide GLP-1RA in development for weight management and the treatment of T2D. This phase 2 double-blind trial evaluated the efficacy and safety of orforglipron in adults with obesity, or with overweight plus at least one weight-related coexisting condition, and without T2D. In total, 272 participants were randomised to orforglipron (12, 24, 36 or 45 mg) or placebo once daily for 36 weeks, with a primary endpoint of change from baseline in body weight at week 26.

more…